Passive (Amyloid-β Immunotherapy attenuates monoaminergic axonal degeneration in the AβPPswe/PS1dE9 mice

Journal of Alzheimer's Disease

Volumn 23, Issue 2, 2011, Pages 271-279

  Liu, Ying ^a   Lee, Michael K ^a,b   James, Maria M ^a   Price, Donald L ^a   Borchelt, David R ^a,c   Troncoso, Juan C ^a   Oh, Esther S ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d 558 Ross Research Building ^*  (United States)

Author keywords

Amyloid ; axon; immunotherapy; neurodegeneration; serotonergic

Indexed keywords

7B6 MONOCLONAL ANTIBODY; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; MONOCLONAL ANTIBODY; SEROTONIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BRAIN CORTEX; CATECHOLAMINE NERVE CELL; CONTROLLED STUDY; DENSITY; HIPPOCAMPUS; IMMUNOTHERAPY; MONOAMINERGIC AXONAL DEGENERATION; MOUSE; MUTANT; NERVE FIBER; NERVE FIBER DEGENERATION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL;

EID: 79951563382     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-101602     Document Type: Article

References (29)

1. Price DL, Sisodia SS (1998) Mutant genes in familial Alzheimer's disease and transgenic models. Ann Rev Neurosci 21, 479-505. (Pubitemid 28150671)
2. McGowan E, Eriksen J, Hutton M (2006) A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 22, 281-289.
3. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT(1997) APPSwtransgenic mice develop age-relatedAbeta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 56, 965-973. (Pubitemid 27386126)
4. Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, Hyman BT (1997) Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 17, 7053-7059. (Pubitemid 27427884)
5. Liu Y, Yoo MJ, Savonenko A, StirlingW, Price DL, Borchelt DR, Mamounas L, Lyons WE, Blue ME, Lee MK (2008) Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J Neurosci 28, 13805-13814.
6. Zweig RM, Ross CA, Hedreen JC, Steele C, Cardillo JE, Whitehouse PJ, Folstein MF, Price DL (1988) The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 24, 233-242.
7. Rub U, Del Tredici K, Schultz C, Thal DR, Braak E, Braak H (2000) The evolution of Alzheimer's disease-related cytoskeletal pathology in the human raphe nuclei. Neuropathol Appl Neurobiol 26, 553-567. (Pubitemid 32049855)
8. Parvizi J, Van Hoesen GW, Damasio A (2001) The selective vulnerability of brainstem nuclei to Alzheimer's disease. Ann Neurol 49, 53-66. (Pubitemid 32163006)
9. Lyness SA, Zarow C, Chui HC (2003) Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging 24, 1-23. (Pubitemid 35454140)
10. Grudzien A, Shaw P, Weintraub S, Bigio E, Mash DC, MesulamMM(2007) Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging 28, 327-335. (Pubitemid 46178530)
11. Holmes C, Boche D,Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebocontrolled phase I trial. Lancet 372, 216-223. (Pubitemid 351978111)
12. Jankowsky JL, Slunt HH, Ratovitski T, JenkinsNA, Copeland NG, Borchelt DR (2001) Co-expression of multiple trans genes in mouse CNS: a comparison of strategies. Biomol Eng 17, 157-165. (Pubitemid 32409891)
13. Tucker SM, Borchelt DR, Troncoso JC (2008) Limited clearance of pre-existing amyloid plaques after intracerebral injection of Abeta antibodies in two mouse models of Alzheimer disease. J Neuropathol Exp Neurol 67, 30-40.
14. Mouton PR, Gokhale AM,Ward NL,West MJ (2002) Stereological length estimation using spherical probes. J Microscopy 206, 54-64. (Pubitemid 34534137)
15. Paxinos G, Franklin KBJ (2001) The Mouse Brain in Sterotaxic Coordinates, Academic Press, San Diego.
16. Kawarabayashi T,Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21, 372-381. (Pubitemid 32107428)
17. Brody DL, HoltzmanDM(2008) Active and passive immunotherapy for neurodegenerative disorders. Ann Rev Neurosci 31, 175-193.
18. Tsai J, Grutzendler J, Duff K, Gan WB (2004) Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci 7, 1181-1183. (Pubitemid 39426234)
19. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14, 837-842.
20. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, LeeVM,HymanBT, Spires-JonesTL(2009) Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A 106, 4012-4017.
21. Tong L, Balazs R, Thornton PL, Cotman CW (2004) Betaamyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J Neurosci 24, 6799-6809. (Pubitemid 38993902)
22. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
23. Geula C (2000) Pathological diagnosis of Alzheimer's disease. In Early Diagnosis of Alzheimer's Disease, Scinto LFM, Daffner KR, eds. Humana, New Jersey, p. 65.
24. German DC, Nelson O, Liang F, Liang CL, Games D (2005) The PDAPP mouse model of Alzheimer's disease: locus coeruleus neuronal shrinkage. J Comp Neurol 492, 469-476. (Pubitemid 41572463)
25. Decker MW, McGaugh JL (1991) The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 7, 151-168.
26. Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, Chen CP, Francis PT, Lasheras B, Ramirez MJ (2005) Cholinergicserotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 43, 442-449. (Pubitemid 40222131)
27. Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ, Hyman BT (2003) Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci 23, 10879-10883. (Pubitemid 37499696)
28. Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE, Mathis CA, Bales KR, Paul SM, Hyman BT, Holtzman DM (2005) Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest 115, 428-433. (Pubitemid 40385484)
29. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.